These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 80433)

  • 1. Cell-mediated cytotoxicity and serum-mediated blocking: evidence that their associated determinants on human tumor cells are different.
    Levy NL
    J Immunol; 1978 Sep; 121(3):916-22. PubMed ID: 80433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Specificity of cell mediated cytotoxicity. I. Cytotoxic reactions in H-2 system after allogeneic sensitization in vivo].
    Schulze HA; Brock J; Siegl E
    Allerg Immunol (Leipz); 1982; 28(2):109-17. PubMed ID: 6182781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas.
    Gately MK; Glaser M; Dick SJ; Mettetal RW; Kornblith PL
    J Natl Cancer Inst; 1982 Dec; 69(6):1245-54. PubMed ID: 6183477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.
    Bishop GA; Marlin SD; Schwartz SA; Glorioso JC
    J Immunol; 1984 Oct; 133(4):2206-14. PubMed ID: 6206157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface antigenic characteristics of human glial brain tumor cells.
    Wikstrand CJ; Mahaley MS; Bigner DD
    Cancer Res; 1977 Dec; 37(12):4267-75. PubMed ID: 72598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-tumor antibodies in the blood of patients with gliomas].
    Martin-Achard A; Diserens AC; de Tribolet N; Zander E; Carrel S
    Schweiz Med Wochenschr; 1978 Jun; 108(25):959-62. PubMed ID: 663586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
    de Vries JE; Spits H
    J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the induction and expression of T cell-mediated immunity. XIV. Antigen-nonspecific oxidation-dependent cellular cytotoxicity (ODCC) mediated by sodium periodate oxidation of cytotoxic T lymphocytes.
    Fan J; Bonavida B
    J Immunol; 1983 Sep; 131(3):1426-32. PubMed ID: 6193189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
    Lee Y; Bigner DD
    Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors.
    Tzeng JJ; Barth RF; Orosz CG; James SM
    Cancer Res; 1991 May; 51(9):2373-8. PubMed ID: 2015600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the activity of cytotoxic murine T lymphocytes by antibodies to idiotypic determinants.
    Rabinowitz R; Schlesinger M
    Immunology; 1980 Jan; 39(1):93-9. PubMed ID: 6155324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor markers of the central nervous system.
    Birkmayer GD
    Cancer Detect Prev; 1981; 4(1-4):231-8. PubMed ID: 7349780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological aspects of experimental brain tumors (review).
    Stavrou D; Bilzer T; Hultén M; Zänker KS; Anzil AP; Haglid KG; Dahme E
    Anticancer Res; 1982; 2(3):151-5. PubMed ID: 6751209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential activation of cytotoxic and suppressor T cells against syngeneic tumors in the mouse.
    Yamauchi K; Fujimoto S; Tada T
    J Immunol; 1979 Oct; 123(4):1653-8. PubMed ID: 90095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity of lymphocyte-mediated cytotoxicity in patients with primary intracranial tumors.
    Levy NL
    J Immunol; 1978 Sep; 121(3):903-15. PubMed ID: 211167
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on the cytolytic attack mechanism of the cytotoxic T lymphocyte (CTL): preparation of antisera against cellfree cytosolic extracts of a CTL clone capable of blocking the lethal hit stage of CTL cytolysis and analysis of the cytolytic structure.
    Hiserodt JC
    J Immunol; 1985 Jul; 135(1):53-62. PubMed ID: 3158707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic determinants in a virus-induced mouse mammary tumor recognized by cell-mediated immune assays.
    Lopez PF; Parks WP; Lopez DM
    J Natl Cancer Inst; 1984 Mar; 72(3):725-32. PubMed ID: 6199544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of sera from SV40-immunized and tumor-bearing hosts for blocking activity and antibody-dependent cellular cytotoxicity.
    Lausch RN; Sofranko J; Prather SO
    J Immunol; 1975 Sep; 115(3):682-7. PubMed ID: 168264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-dependent cellular cytotoxicity (ADCC) and lymphocyte-mediated cytotoxicity (LMC) in patients with vascular disease and guinea pigs immunized with human vascular extracts.
    Horváth M; Varsányi M; Jovanovich N
    Allergol Immunopathol (Madr); 1983; 11(4):261-71. PubMed ID: 6606348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complexity of factors in sera of different mice that affect MTV-induced mammary tumor cells.
    Blair PB; Lane MA; Mar P
    J Immunol; 1976 Mar; 116(3):610-4. PubMed ID: 176267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.